Novel agents in acute myeloid leukemia

International Journal of Hematology

Volumn 96, Issue 2, 2012, Pages 178-185

  Ungewickell, Alexander ^a   Medeiros, Bruno C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; DNMT inhibitors; HDAC; NEDD8 activating enzyme inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; [4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; AZACITIDINE; BARASERTIB; BELINOSTAT; CPX 351; CYTARABINE; DAUNORUBICIN; ENTINOSTAT; GANETESPIB; GEMTUZUMAB OZOGAMICIN; HEAT SHOCK PROTEIN 90; IDARUBICIN; LENALIDOMIDE; PANOBINOSTAT; POMALIDOMIDE; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION; LIVER FUNCTION TEST; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN-SERINE-THREONINE KINASES; RESEARCH DESIGN; THALIDOMIDE; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84866927894     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1151-5     Document Type: Article

References (42)

1. Fernandez HF, et al. Anthracycline dose intensification in acute myeloid leukemia. New Engl J Med. 2009;361:1249-59.
2. Döhner H, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.
3. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29:495-503.
4. Sanz MA, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-91.
5. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. New Engl J Med. 2010;363:2424-33.
6. Delhommeau F, et al. Mutation in TET2 in myeloid cancers. New Engl J Med. 2009;360:2289-301.
7. Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348-55.
8. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med. 2009;361: 1058-66.
9. Appelbaum FR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-5.
10. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116:2224-8.
11. Richardson PG, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-7.
12. Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
13. Fehniger TA, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117:1828-33.
14. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2012:1-10.doi:10.1038/nm. 2305.
15. Esteller M. Epigenetics in cancer. New Engl J Med. 2008;358: 1148-59.
16. Baylin SB. Resistance, epigenetics and the cancer ecosystem. Nat Med. 2011;17:288-9.
17. Sudan N, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006;107:1839-43.
18. Blum W, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107:7473-8.
19. Fenaux P, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-9.
20. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556-61.
21. Scandura JM, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118:1472-80.
22. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152:524-42.
23. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008;22:1680-4.
24. Garcia-Manero G, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521-7.
25. Piekarz RL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827-34.
26. Olsen EA, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-15.
27. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009;27:5459-68.
28. Gore SD, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361-9.
29. Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol. 2012;90:14-22.
30. Garcia-Manero G, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012. doi:10.1200/JCO.2011.8.3265.
31. Emanuele MJ, et al. Global identification of modular cullin-RING ligase substrates. Cell. 2011;147:459-74.
32. Swords RT, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010;115:3796-800.
33. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-72.
34. Lancet JE, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010;24:699-705.
35. Tardi P, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129-39.
36. Feldman EJ, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979-85.
37. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007;8: 798-812.
38. Oke A, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009;69:4150-8.
39. Lowenberg B, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011;118:6030-6.
40. Ho J, et al. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer. 2006;6:263.
41. Smith CC, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;1-6. doi:10.1038/ nature11016.
42. Roychowdhury S, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra121.